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Abstract
Background: Tetralogy of Fallot is a congenital heart disease that requires surgical repair without which survival through
childhood is extremely rare. The aim of this paper is to use data from the mandatory follow-up of patients with Tetralogy of
Fallot to model the health-related costs and outcomes over the first 55-years of life.
Method: A decision analytical model was developed to establish costs and outcomes for patients up to 55 years after
diagnosis and first repair of Tetralogy of Fallot compared to natural progression. Data from Adult Congenital Heart Disease
(ACHD) centres that follow up Tetralogy of Fallot patients and Great Ormond Street Hospital (GOSH), London, United
Kingdom (UK) medical records was used to establish the cost and effectiveness of current interventions. Data from a Czech
cohort was used for the natural, no intervention condition.
Results: The average cost per patient of a repair for Tetralogy of Fallot was £26,938 (SE = £4,140). The full life time cost per
patient, with no discount rate, was £65,310 (95% CI £64,981–£65,729); £56,559 discounted (95% CI £56,159–£56,960).
Patients with a repair had an average of 35 Quality Adjusted Life Years (QALYs) per patient over 55 years undiscounted and
20.16 QALYs discounted. If the disorder was left to take its natural course, patients on average had a total of 3 QALYs per
patient with no discount rate and 2.30 QALYs discounted.
Conclusion: A model has been developed that provides an estimate of the value for money of an expensive repair of a
congenital heart disease. The model could be used to test the cost-effectiveness of making amendments to the care
pathway.
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Introduction
Tetralogy of Fallot is the commonest cyanotic heart condition
and was one of the first congenital heart diseases of any complexity
to be repaired [1]. The condition affects about 0.31/1000 live
births [2], with approximately 250 repairs of Tetralogy of Fallot
being undertaken annually in the United Kingdom (UK) [3].
Survivors of the surgery in its ground-breaking era form a cohort
of patients with a ‘new disease’ whose natural history they are
themselves delineating.
Currently, the diagnosis of Tetralogy of Fallot may be achieved
through pre-natal ultrasound screening or emerge at the time of an
emergency presentation in infancy or during investigation of a
murmur or an intercurrent illness. All patients require surgical
repair without which survival through childhood is extremely rare.
The repair is not fully ‘corrective’, primarily because obstruction
in the area between right ventricle and pulmonary artery must be
relieved, often sacrificing pulmonary valve function. Service
standards require lifetime follow up for all Fallot patients [4].
For some, surgical revision of the right ventricular outflow tract
area is required later – most usually a pulmonary valve
replacement (PVR). Though for an individual patient, the future
need for PVR is hard to judge in early childhood, cohort studies
are emerging that permit prediction of the proportions requiring
later revision [5].
Achieving early surgical survival required a demanding learning
curve – 30-day mortality rates were commonly around 25% in the
1960s and are currently around 10-times lower. Because early
outcomes have been good for many years, the great majority of
children currently treated leave ‘childhood’ services fit to face
adult life [6]; they are looked after by a network of specialist Adult
Congenital Heart Disease (ACHD) centres. With the benefit of a
primary data source - a cohort of Fallot patients 1964–2009 - our
aim was to estimate the first 55 years health-related costs and
outcomes for patients with Tetralogy of Fallot born now and
managed by current standards.
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Methods
Decision analytic models use the best available information
from a range of sources to estimate the costs and consequences of a
particular intervention or policy, providing they take into account
the uncertainty associated with the variables contained in the
model [7]. We developed a decision analytic model to calculate the
health outcomes and costs of surgical repair of Tetralogy of Fallot
over a 55 year time horizon. The primary data source is a
complete consecutive list of all UK patients having repair of
uncomplicated Tetralogy of Fallot at Great Ormond Street
Hospital (GOSH), London, UK, from February 1964 to January
2009. Secondary data sources have been used where necessary.
Great Ormond Street Hospital Cohort
Data was available on all 1085 UK patients who had a repair of
Tetralogy of Fallot at GOSH from February 1964 to January
2009. The GOSH medical records provided date and age at
repair, dates of any PVRs and dates of death if these events
occurred in childhood. Demographic data was also linked to NHS
numbers, providing information about deaths since 1996 and
collaborators from each ACHD centre used local databases to
provide dates of any PVRs done for patients over the age of 16.
The 46 patients lost to follow-up were censored on the last date of
follow-up recorded.
Parents of current patients are asked to give written consent for
patient details to be collected and stored for audit and research
purposes. The NHS Research Ethics Committee approved the
collection and storage of resource use information from medical
records from unconsented patients including the use of NHS
numbers for later tracking.
Survival and Reoperation-free Survival
Natural survival for Tetralogy of Fallot patients with no repair
was estimated from Samenek (1992) where data on incidence of
congenital heart disease (CHD) was combined with date of death
to determine the distribution of age at death for all children with
CHD in Central Bohemia, Czechoslovakia, over a 27 year period
[8]. No intervention for Tetralogy of Fallot was available at the
time hence the observational study provides data on the attrition of
the disease without intervention. This information was used to
construct a parametric (Weibull) survival model.
The 1085 patients in the GOSH cohort data provided the
inputs for the parametric models (Weibull) we used to summarise
survival from birth, with and without PVR. This was done in line
with methodology set out in Briggs et al [9].
All analyses were conducted in Stata v10.
Resource Usage: Frequencies
Age specific frequencies of routine health interventions were
based on data from the cohort as follows:
Resource Usage: between Birth and Open Heart Repair
We used data from patients born since 2000 to populate the
model for this phase. In clinical terms, this period includes the
phase of presentation and diagnosis, preoperative investigations
and surveillance. Of the 214 patients in the cohort born in this era,
30 were selected at random and the in-patient and outpatient
events and investigations each received were aggregated from their
clinical records. Presentation was coded as ‘antenatal diagnosis’,
‘presentation with emergency hospital admission’ or ‘diagnosis
achieved in an out-patient context’. Hospital lengths of stay,
diagnostic and assessment investigations and numbers of out-
patient visits were aggregated for these patients to represent the
current pre-operative costs. There were no deaths in this interval.
Resource Usage: Admission for Open Heart Repair
Actual data from the same 30/214 patients were used to
estimate multipliers for the current costs for the open heart
Figure 1. Markov model of health states for repair cohort.
doi:10.1371/journal.pone.0059734.g001
Table 1. Average resource use per patient: Mean (SE).
Resource Birth to first repair First decade following repair Resource use per decade (2+)
N=30 N=21 N=14
Outpatient appointment 3.27 (0.42)
ECHO 6.07 (0.4) 0.62 (0.02) 2 (0.62)
MRI 0.13 (0.1) 0.33 (0.14) 1.93 (0.41)
ECG 1.43 (0.2) 0.24 (0.15) 3.21 (0.75)
24 hr ECG 0.13 (0.06) 0.1 (0.07) 1.57 (0.37)
Ultrasound 0.73 (0.3)
X-ray 8.77 (1.3) 0.14 (0.14) 2.5 (0.99)
ECMO 0.03 (0.03)
Preliminary procedure 0.17 (0.03)
Other Cardiac Surgery 0.05 (0.05) 0.07 (0.07)
Exercise lab 0.14 (0.08) 1.29 (0.41)
doi:10.1371/journal.pone.0059734.t001
Lifetime Costs and Outcomes of Tetralogy of Fallot
PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e59734
Figure 2. The changing proportion over time between 0 and 55 years in which patients are in 3 exhaustive and mutually exclusive
states: ‘dead’, ‘alive without PVR’ and ‘PVR’. A) With repair; B) Natural progression, no repair.
doi:10.1371/journal.pone.0059734.g002
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operation. The data used included the cost of the operation, length
of stay, ward type and any major postoperative complications.
Resource Usage: between Open Heart Repair and 10
Years of Age
Data from the same patients repaired since 2000 and who have
not already required a PVR were used to estimate the current costs
of postoperative surveillance, largely outpatient visits and inves-
tigations up to age 10. Interventions, whether catheter-based or
surgical but which did not constitute a PVR were aggregated and
the counts used as multipliers for these events.
Resource Usage: Age 10–20 and Subsequent Decades
Clinical events (primarily out-patient visits and investigations)
from age 10–20 of all twenty-one surviving operated patients born
in 1990 were aggregated and rendered as an annual estimate of
the clinical event rate for patients aged 10–20. We assumed that
the rate of clinic visits and investigations would remain at rates
similar to those at ages 10–20 for subsequent decades. Re-
interventions short of PVR were aggregated as before.
Cost of PVR
Data from the same 30/214 patients repaired since 2000 were
used to estimate multipliers for the current costs for PVR. Data
used related to length of stay and major postoperative interven-
tions.
Resource Usage: Costs
Based on the above cohorts we calculated the average resource
use from birth until first repair, per decade and per PVR for
patients who have a second repair. Per decade costs were divided
by 10 to obtain a weighted cost per patient per year. All costs were
in British Pounds (£) and 2010/2011 values. Unit costs for
interventions and investigations other than first repair, PVR and
Extracorporeal Membrane Oxygenation (ECMO) were derived
from reference costs 2010/2011 [10].
The cost of the open repair was obtained from the GOSH
patient level costing system for 30/214 Tetralogy of Fallot
patients. This was divided by the 2010 GOSH market forces
factor to obtain a UK average cost of repair. It was assumed that a
PVR operation itself would have the same cost as the primary
repair operation, although additional costs for length of stay and
additional procedures were handled separately.
The cost of ECMO was obtained from Brown et al, and was
estimated at £10,539 per day over 6 days for a total cost per
ECMO of £75,126, accounting for inflation [11].
Quality of Life
From the complete consecutive list, 50 survivors (10 from each
surgical decade 1960’s to 2000’s) were chosen at random to receive
a Quality of Life questionnaire; these patients (age 4–55) were
assumed to be representative of survivors generally. In the absence
of a generic quality of life instrument applicable across child and
adult populations, the PEDSQL was administered to those age 1–
18 and WHOQOL Bref to the adults.
Figure 3. Cost-effectiveness plane – cost per Fallot patient over 55 years graphed against the QALY gained compared to natural
progression –10,000 simulations.
doi:10.1371/journal.pone.0059734.g003
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The outcome measure used in the model was quality adjusted
life years (QALYs). QALYs represent both the quality and
quantity of health related quality of life, quality being measured
by utility scores. A utility score of 1 represents perfect health and a
utility of 0 death; negative values, representing states worse than
death, are possible. QALYs are the recommended outcome for use
in economic evaluations in the UK as they are a common unit that
allow for comparable decisions about resource allocation across
different diseases. In England, to ensure consistency of approach,
the National Institute for Health and Clinical Excellence (NICE)
recommends that utility scores used to calculate QALYs are
calculated from the EuroQol 5D (EQ-5D), a 5 domain 3 level tool,
and an algorithm developed by Dolan which is based on
valuations of a selection of the 243 potential EQ-5D health states
by 3,995 members of the general population [12].
There are no utility scores to calculate QALYs available for the
WHOQOL. Instead we used a methodology similar to that used
by Al Ruzzeh et al [13] to calculate utility scores from the
WHOQOL; responses to WHOQOL questions which are similar
to the EQ-5D dimensions were used to calculate utility scores. The
utility values for the 5 level cross walk EQ-5D value set [14] were
used so there was no need to covert the 5 levels of the WHOQOL
to 3.
Similarly there are no utility scores available for PEDSQL, so
the same methodology was used again but instead the questions
are similar to those of the Child Health Utility 9D (CHU9D), for
which utility scores are available [15]. We used the CHU9
algorithm applied to PEDSQL to calculate average utility for
patients under 18.
As there is no quality of life (QoL) data available for the natural
progression, for the ‘no surgical repair’ comparator cohort a
random number between 0 and 1 was chosen to represent their
utility scores.
Description of Model
The model used a time dependent Markov model, as described
above, to simulate time to death from first repair, time to PVR and
time to death from PVR over 55 years (see figure 1). The
hypothetical population in the model is assumed to have the same
characteristics as the cohort of patients described above.
The model was built in Microsoft Excel 2010 and is available as
supporting material (Model S1).
Cost Effectiveness Analysis and Probabilistic Sensitivity
Analysis
Cost effectiveness was calculated as the incremental cost, in
British Pounds (£’s), per QALY gained from surgical repair of
Tetralogy of Fallot compared to natural progression, no repair.
This provides a summary of the incremental, or extra, costs of the
surgical repair plus all heart related follow up appointments,
divided by the incremental, or extra, benefits.
A probabilistic sensitivity analysis (PSA) was conducted to
calculate the cost effectiveness of surgical repair using the net
monetary benefit approach as set out in Briggs et al [9]. These
values were used to generate a cost effectiveness acceptability
Figure 4. Cost effectiveness acceptability curve comparing repair of Tetralogy of Fallot with no repair: undiscounted (solid line)
and discounted (dashed line).
doi:10.1371/journal.pone.0059734.g004
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curve to determine the probability that surgical repair of Tetralogy
of Fallot is cost effective for a hypothetical willingness to pay for
each additional QALY gained for values of between £0 and
£20,000. Results are based on 10,000 simulations. We provided
results for undiscounted and discounted models. The discount rate
was randomly varied between 0% and 6% in line with NICE
guidance [12].
Results
Costs
A summary of the average resource use per patient is reported
in Table 1. The average cost per patient of the admission including
repair of Tetralogy of Fallot was £26,938 (SE=£4,140). In 2010
GOSH had a market forces factor of 1.18 [16]. After applying the
market forces factor, the average UK cost for a repair was
calculated as £22,829. The mean full life time cost per patient,
with no discount rate, is £65,310 (95% CI £64,981–£65,729) and
£56,559 discounted (95% CI £56,159–£56,960).
Mortality and Quality of Life
Figure 2 provides a summary of the proportion of patients in
each health state over time for the two models. The utility score for
patients under 18 with a repair was 0.83 (SE= 0.031) and 0.72
(SE= 0.037) for adult patients. Patients with a repair had an
average total of 35 QALYs with an average total of 3 QALYs for
patients with no repair.
Incremental Cost per QALY Gained
The mean cost per QALY gained over 10,000 simulations was
£2027 without discounting (£3168 discounted). All simulations
fall into the north-east quadrant of the cost-effectiveness plane, in
that all simulations result in more QALYs but also cost more
(figure 3). Based on a willingness to pay of £20,000 per QALY
gained there is a 100% chance that open repair of Tetralogy of
Fallot is cost effective compared to doing nothing (figure 4).
Figure 5 shows the proportions of overall costs attributable to
the surgery, inpatient stays in intensive care and high dependency
units, outpatient appointments and investigations.
Discussion
This model provides information on the first 55 years costs of
the common congenital heart problem Tetralogy of Fallot and
compares it to the additional gain in QALYs. The first 55 years
cost of a Fallot patient to the NHS is approximately £65,310. This
cost is outweighed by the additional years of life gained in
reasonably full health. Ungerleider et al [17] published estimates
of hospital costs of repairing Tetralogy of Fallot, including an
evaluation of the alternatives of primary repair versus repair after
preliminary palliative procedures. However we believe this is the
first time a full cost effectiveness evaluation has been attempted in
the field of childhood heart disease.
Limitations
Surgery for Tetralogy of Fallot only emerged in the 1960’s,
hence the postoperative ‘‘natural history’’ beyond age 55 is
unknown; Fallot patients’ underlying biology makes it conceivable
Figure 5. Breakdown of health care costs for Tetralogy of Fallot patients from birth to age 55: undiscounted.
doi:10.1371/journal.pone.0059734.g005
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that heart related costs could escalate in later life. The natural
progression, or no intervention, approach had only limited data
from historical observational studies where no intervention was
available, as it would be unethical to collect further information
currently. None the less, this model presents confirmation of the
benefit of expensive childhood interventions that significantly
improve survival and quality of life of patients. Quality of life of
surgical patients would need to decrease by 85% before the added
life expectancy provided no additional benefit because of poor
quality of life, even assuming perfect health for the ‘do nothing’
approach.
The results for both the discounted and undiscounted models
have been presented; it is arguable which should be used in a
context where surgery is offered to an infant as an ‘investment’ for
their adult life. For patients living to the age of 55, using a discount
rate of 3.5%, a year of life lived in perfect health is worth less than
half a QALY. This seems to undermine the purpose of the
intervention, which is to increase the chance that the patient
reaches adult life in close to full health. This is supported by the
evidence that people would like to give greater weight to younger
people to represent the additional potential life they have to lose or
gain. Trying to formalize the measurement of this though has
proved difficult [18].
Conclusions
Repair of Tetralogy of Fallot is a worthwhile investment for the
health care system given the QALYs gained. This model could be
used as a baseline to test the cost-effectiveness of changes to the
care pathway for Fallot babies. Such changes could include
improving screening procedures, changes in conduct of the
primary repair with a view to changing the long term incidence
of PVR and trials of the impact of elective PVR in adult life – all
substantive questions for the congenital heart disease community.
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